Palvella Therapeutics, Inc. (PVLA) Revenue (2016 - 2022)
Palvella Therapeutics (PVLA) has disclosed Revenue for 11 consecutive years, with -$47000.0 as the latest value for Q3 2024.
- On a quarterly basis, Revenue fell 101.19% to -$47000.0 in Q3 2024 year-over-year; TTM through Dec 2024 was $6000.0, a 100.05% increase, with the full-year FY2024 number at -$430000.0, down 110.49% from a year prior.
- Revenue was -$47000.0 for Q3 2024 at Palvella Therapeutics, down from $6000.0 in the prior quarter.
- In the past five years, Revenue ranged from a high of $20.2 million in Q2 2023 to a low of -$37.4 million in Q4 2023.
- A 5-year average of $3.7 million and a median of $4.0 million in 2023 define the central range for Revenue.
- Peak YoY movement for Revenue: surged 629.64% in 2021, then crashed 709.12% in 2023.
- Palvella Therapeutics' Revenue stood at $1.5 million in 2020, then soared by 629.64% to $11.1 million in 2021, then tumbled by 44.55% to $6.1 million in 2022, then plummeted by 709.12% to -$37.4 million in 2023, then skyrocketed by 99.87% to -$47000.0 in 2024.
- Per Business Quant, the three most recent readings for PVLA's Revenue are -$47000.0 (Q3 2024), $6000.0 (Q2 2024), and $47000.0 (Q1 2024).